The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

Cancer cells survive therapy by dynamically rewiring their metabolism in response to nutrient availability, ...

The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).

Researchers found in mice that multiple nutrients and cancer cell characteristics work together to control the spread of ...

Tumor growth unfolds within a tumor microenvironment (TME) defined by metabolic–immune crosstalk. Emerging evidence indicates that cancer cells not only reprogram glycolysis but also alter amino acid, ...

Dysbiosis of the gut microbiota compromises intestinal mucosal barrier function, primarily characterized by downregulation of tight junction proteins in intestinal epithelial cells, consequently ...

Amino acid metabolism in the TIME. The TIME is shaped by metabolic competition between tumor and immune cells. Amino acids have key roles in modulating immune responses and tumor progression. (A) ...